Growth Stocks To Follow Today - April 25th
Read Our Latest Research Report on BX
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of Novo Nordisk A/S stock traded down $0.55 during trading on Friday, reaching $62.08. The company had a trading volume of 4,245,694 shares, compared to its average volume of 6,074,437. The company has a market cap of $278.59 billion, a price-to-earnings ratio of 18.82, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm’s fifty day moving average is $74.03 and its 200-day moving average is $90.18. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.
Read Our Latest Research Report on NVO
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Shares of SWTX stock traded down $0.40 on Friday, hitting $44.54. 4,301,662 shares of the stock traded hands, compared to its average volume of 1,451,764. The company’s fifty day moving average is $46.43 and its 200 day moving average is $40.41. SpringWorks Therapeutics has a 1-year low of $28.21 and a 1-year high of $62.00. The company has a market capitalization of $3.34 billion, a PE ratio of -12.79 and a beta of 0.79.
